Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Virologic Response Rates in the APRICOT Study

for Health Care Providers

Table 8. Virologic Response Rates in the APRICOT Study

Back to HIV Coinfection Recommendations

INF alfa-2a 3 MIU. tiw + RBV 800 mg/day x 48 wkPeg INF alfa-2a (PEGASYS) 180 µg/wk + placebo x 48 wk Peg INF alfa-2a (PEGASYS) 180 µg/wk + RBV 800 mg/day x 48 wk
*p = 0.0078 versus IFN + RBV; ** p < 0.0001 versus IFN + RBV, p < 0.0001 versus PEG only.
n = 285n = 286n = 289
ETR (Overall)14%33%49%
Genotype 18%21%38%
Non-Genotype 1 27% 57%64%
SVR (Overall)12%20%*40%**
Genotype 17%14%29%
Non-Genotype 1 20% 36% 62%